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Capecitabine as a Radiosensitizing Agent in Neoadjuvant Treatment of 
Locally Advanced Resectable Rectal Cancer: Prospective Phase II Trial
Aim To evaluate the efficacy and toxicity of preoperative chemoradiotherapy 
with capecitabine in locally advanced rectal cancer.
Methods Between June 2004 and January 2005, 57 patients with operable, 
clinical stage II-III adenocarcinoma of the rectum entered the prospective 
phase II study. Radiation dose was 45 Gy (25 × 1.8 Gy). Concurrent chemo-
therapy with a daily dose of 1650 mg/m2 capecitabine was administered orally, 
divided into two equal doses per day, including weekends. Patients were evalu-
ated weekly for acute toxicity and compliance with the protocol. Surgery was 
scheduled 6 weeks after the completion of the chemoradiotherapy.
Results A single female patient died after receiving 27 Gy, because of pulmo-
nary embolism. All other patients completed the preoperative chemoradio-
therapy according to the protocol and a definitive operation was performed in 
all but one of these patients. The complete pathological response was recorded 
in 5 patients (9.1%). Tumor (T), lymph nodes (N), and overall downstaging 
rates were 40%, 52.9%, and 49.1%, respectively. Total sphincter preservation 
rate was 65.5% (36 out of 55 patients) and the rate in 27 patients with tumors 
located within 5 cm of the anal opening was 37% (10 out of 27 patients). The 
most frequent side-effect of the combined therapy was dermatitis (grade 3 in 
19 patients). After surgery, a single patient died due to sepsis during the early 
perioperative period. Nonlethal perioperative complications were recorded in 
24/55 patients.
Conclusion Preoperative chemoradiotherapy with oral capecitabine is safe 
and well tolerated. It has a downstaging potential and can increase the pos-
sibility for sphincter preservation surgery.
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Clinical Science
Preoperative chemoradiation has become a standard part of treat-
ment protocols in stage II and III rectal cancer. Compared to post-
operative chemoradiotherapy, the advantage of preoperative ap-
plication of chemotherapeutics and irradiation includes improved 
compliance, reduced toxicity, and downstaging of the tumor in a 
substantial number of patients. The latter may enhance the rate of 
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curative surgery, permit sphincter preservation in 
patients with low-sited tumors, and have a positive 
impact on the quality of life of these patients (1).
Although several innovative agents are being 
investigated in combination with radiotherapy, 
5-fluorouracil (5-FU) in continuous infusion re-
mains the gold standard in preoperative chemo-
radiotherapy schedules. The prolongation of 
exposure of cells to 5-FU results in improved an-
titumor activity, but requires prolonged infusion, 
usually through a vascular access port (VAP). 
Complications resulting from long-term venous 
access, such as bleeding and thrombosis, are not 
uncommon (2).
Orally administered capecitabine (Xeloda®, 
Hoffmann-La Roche Ltd, Basel, Switzerland) 
mimics the pharmacokinetics of continuous 5-
FU infusion and makes chemoradiotherapy more 
patient-friendly. The mechanism of capecitabine 
activation, preferably in tumor cells, may further 
enhance its efficacy and tolerability, offering the 
potential for an enhanced therapeutic ratio (3-
5). The use of capecitabine allows chronic dosing 
and, at the same time, avoids the discomfort and 
complications associated with prolonged intrave-
nous infusion of 5-FU (2,6). Thus, the majority 
of patients prefer oral chemotherapy to 5-FU in-
fusions (7).
The aim of the present prospective phase II 
study was to evaluate the efficacy and toxicity of 
preoperative chemoradiotherapy with capecitabi-
ne in patients with locally advanced rectal cancer. 
The primary endpoint of the study was a patho-
logically determined complete remission rate of 
the disease, locally and regionally. Secondary out-
comes were the rate of sphincter preservation in 




The inclusion criteria were: histologically verified 
adenocarcinoma of the rectum, clinical TNM 
stage II or III (8); no prior radiotherapy and/
or chemotherapy; World Health Organization 
(WHO) performance status <2 (9); age at diag-
nosis of 18 or older; and adequate bone marrow, 
liver, renal, and cardiac function (no history of 
ischemic heart disease). A history of prior malig-
nancy other than non-melanoma skin cancer or 
in situ carcinoma of the cervix rendered the pa-
tient ineligible.
Before treatment, all patients received de-
tailed oral and written information on the treat-
ment protocol and possible side effects, and 
signed an informed consent. The trial was ap-
proved by the Independent Ethical Committee 
of the Institute of Oncology, Ljubljana, Slovenia.
Pre-treatment evaluation
The pre-treatment work-up comprised a com-
plete history, physical examination, complete 
blood count, serum biochemistry, carcinoembry-
onic antigen (CEA), chest radiography, ultraso-
nography (US), and/or computer tomography 
(CT) of the whole abdomen, and colonoscopy 
with biopsy. Locoregionally, the extent of disease 
was determined by endoscopic US (67%), CT 
scan (23%), magnetic resonance imaging (MRI) 
of the abdomen (5%), or the combination of 
these methods (5%).
Treatment protocol
Radiotherapy was delivered using 15 MV pho-
ton beams and four-field box technique, once per 
day, 5 days a week. The small pelvis received 45 
Gy in 25 fractions over 5 weeks. Three-dimen-
sional CT-based treatment planning was per-
formed. The clinical target volume was defined 
to cover the small pelvis from the L5-S1 inter-
space to 5 cm below the primary tumor. The lat-
eral borders were 5 mm outside the true bony 
pelvis. The posterior margin covered the sacrum, 
and the anterior margin encompassed the poste-
rior one-third to one-half of the bladder and/or 
vagina. An additional 1 cm in all directions was 
added to the clinical target volume to obtain the 
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planning target volume. The dose was prescribed 
to cover the planning target volume with a 95% 
reference isodose (95% of the ICRU point dose). 
Patients were treated in the prone position. They 
were instructed to have a full bladder during irra-
diation, and no devices were used to displace the 
small bowel out of the irradiated volume. A mul-
tileaf collimator was used for shaping the fields 
and for the protection of normal tissues.
Chemotherapy was administered con-
comitantly with radiotherapy and consisted of 
capecitabine administered orally at a daily dose 
of 1650 mg/m2, divided into two equal doses 
given 12 hours apart. One of the doses was tak-
en 2 hours prior to irradiation. The chemother-
apy started on the first day of radiotherapy and 
finished on the last day of radiotherapy (includ-
ing weekends). Whenever radiotherapy was in-
terrupted (treatment-related toxicity, machine 
breakdown or any other reason), chemotherapy 
was not administered.
During treatment, patients were evaluated 
weekly to assess acute toxicity and compliance 
with the treatment schedule. Clinical examina-
tion and complete blood count were performed 
and body weight was measured. Toxic side effects 
were assessed according to National Cancer In-
stitute Common Toxicity Criteria (NCI-CTC), 
version 2.0 (10).
Definitive surgery was scheduled for 6 weeks 
after the completion of chemoradiotherapy. Sur-
gical management included a sphincter preser-
vation approach whenever possible, using the 
total mesorectal excision technique. After the 
operation, pathologic evaluation of the surgical 
specimen was performed in the hospitals where 
patients were operated on. The pathologists fol-
lowed the uniform guidelines when examining the 
tissue specimen obtained during rectal surgery.
The effect of preoperative chemoradiotherapy 
on tumor downstaging was assessed by compar-
ing the pretreatment radiologically determined 
TNM stage with the postoperative pathologic 
TNM stage (Figure 1).
Statistical analysis
The pathologically determined complete re-
mission rate was the main endpoint. Accord-
ing to the results of the NSABP R-03 (11) and 
the study by Sauer et al (1), a pathologically de-
termined complete remission rate of 8% can be 
expected using infusional 5-FU and concomi-
tant radiotherapy, while in a limited number of 
preliminary reports using capecitabine with ra-
diotherapy, pathologically determined complete 
remission rates of 4%-31% were reported. We 
aimed to evaluate whether we could produce a 
12% pathologically determined complete remis-
sion rate with our approach, but not lower than 
4%. Setting 4% as the lowest pathologically de-
termined complete remission rate of interest, 
with an alpha error of 5%, and a power of 80%, 
at least 55 evaluable patients were needed (calcu-
lated using power sample calculation, for single 
sample, percentages, α = 5%, 1-β = 20%, http://
www.dssresearch.com/toolkit/sscalc/size_p1.asp).
Pathologically determined complete remis-
sion rates with 95% confidence intervals (CI) 
were reported. The dependence of pathological-
ly determined complete remission rate and treat-
ment intensity was tested using the two-tailed 
Fisher exact test. Statistical analysis was per-
Figure 1. Study flowchart.
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formed using the Statistical Package for the So-
cial Sciences, version 12.0 (SPSS Inc., Chicago, 
IL, USA).
Results
Between June 2004 and January 2005, 57 pa-
tients entered the study. There were 43 men and 
14 women, with a median age of 67 years (range 
34-81 years). The WHO performance status was 
graded as 0 in 52 patients and as 1 in 7 patients. 
According to the UICC TNM classification 
system, the extent of the disease was as follows: 
T3N0 – 20, T4N0 – 1, T1N1 – 1, T2N1 – 2, 
T3N1 – 26, T4N1 – 3, and T3N2 – 4 patients. 
The median distance of the tumor from the anal 
opening was 5.5 cm (range 1–12 cm). In 28 pa-
tients, the primary tumor was sited 5 cm or less 
from the anal opening. (Table 1).
Treatment compliance
Out of the 57 patients in the study, a single fe-
male patient died after receiving 27 Gy due to 
pulmonary embolism originating from deep ve-
nous thrombosis of the lower extremity, most 
probably not related to preoperative chemoradio-
therapy. The other 56 patients (98%) completed 
the preoperative chemoradiotherapy according 
to the protocol. They all received the total dose 
of 45 Gy in 25 fractions of 1.8 Gy. Radiothera-
py treatment was completed in the median time 
of 33 days (range 29-43 days). The median time 
of radiotherapy interruption was 2 days (range 1-
6 days) and was recorded in 25 (45.6%) patients 
(machine breakdown, 21 patients; treatment-re-
lated toxicity, 4 patients). The median duration 
of chemotherapy was 33 days (range 8-50 days) 
and median time of chemotherapy interruption 
was 3 days (range 1-13 days). Because of poor 
compliance, 5/55 patients received less than 90% 
of the planned capecitabine dose, whereas in 3 
additional patients the reasons were ischemic 
cardiac manifestation, nausea with vomiting, and 
low leukocyte count.
After chemoradiotherapy, 55 of 56 patients 
underwent definitive surgery performed by 24 
surgeons in 10 hospitals all over Slovenia. In one 
patient, only explorative laparotomy was per-
formed, as the tumor was deemed to be inopera-
ble. Patients were operated on 13 to 87 days (me-
dian 45 days) from the last day of preoperative 
chemoradiotherapy. However, 93% (52/56) of 
the patients had surgery 5 to 7 weeks after finish-
ing chemoradiation, whereas in other 4 patients 
the reasons for wide interval between chemora-
diotherapy and surgery were ileus, additional pre-
operative diagnostics, or poor general condition 
of two patients. The types of operations were as 
follows: low anterior resection − 32 (58.2%); ab-
dominoperineal resection − 17 (30.9%); anterior 
resection – 4 (7.3%); exenteration of the small 
pelvis − 1 (1.8%); and Hartmann’s resection – 1 
(1.8%). As determined by histopathological ex-
amination of surgical specimens, the resection 
was radical (R0) in 54 patients. In one patient, 
microscopic foci of cancer cells were found in the 
surgical margin (R1 resection).
Toxicity
Preoperative chemoradiotherapy was well tol-
erated in the majority of patients and no treat-
Table 1. Characteristics of 57 patients and tumors included in 
prospective phase II trial on preoperative chemoradiotherapy 
with capecitabine in locally advanced rectal cancer
Characteristics No. (%)
Age (years; median and range) 67 (34-81)*
Gender:
 male 43 (75.4)
 female 14 (24.6)
WHO performance status:*
 stage 0 52 (91.2)
 stage I  7 (8.8)
Tumor differentiation (grade):
 well (G1)  4 (7)
 moderate (G2) 21 (36.8)
 poorly (G3)  3 (5.3)
 unknown or not stated (GX) 29 (50.9)
Tumor distance from the anal opening 
 (cm; median and range)
 5.5 (1-12)
Type of surgery:†
 anterior resection  3 (5.3)
 low anterior resection 26 (45.6)
 coloanal reconstruction  3 (5.3)
  abdominoperineal resection 25 (43.9)
*WHO performance status (9).
†As planned before the start of preoperative chemoradiotherapy.
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ment-related mortality was observed, except for 
the patient who died because of pulmonary em-
bolism. The frequency and intensity of treat-
ment-related acute toxicities in 55 patients who 
underwent definitive surgery are listed in Table 
2. The most frequent and serious side-effect of 
the combined therapy was dermatitis, occurring 
as grade 3 in 19 (34.5%) patients. During this pe-
riod, 29 (52.7%) patients lost weight in compar-
ison with the beginning of treatment. The maxi-
mum body weight loss was 17.5% (median 3.8%, 
range 1.2%-17.5%). Of the remaining patients, 19 
(34.5%) succeed in maintaining a constant weight, 
and in 7 (12.7%) patients weight increased up to 
11% (median 6.9%, range 1.1%-11%).
After surgery, one patient died due to sepsis 
during the early perioperative period. Non-lethal 
perioperative complications were recorded in 24 
of 55 patients: delayed healing of postoperative 
wound in 12 (21.8%) patients, febrile episode 
in 5 (9.1%) patients, ileus in 3 (5.5%) patients, 
chronic diarrhea in 3 (5.5%) patients, and anas-
tomotic leakage in 1 (1.8%) patient.
Tumor response
Tumor response was evaluated in 55 patients 
who had definitive surgery. In 2 of them, liver 
metastases were found during the operation. 
No signs of liver metastases were recorded in 
preoperative radiological studies in either of 
the two.
The overall downstaging rate was 49.1% (ie, 
in 27/55 patients): decrease in T-and N-stage 
were observed in 22 (40%) and 18 (52.9%) pa-
tients, respectively. The increase in T- and/or 
N-stage (upstaging) was recorded in 6 patients 
(10.9%). Pathologic TNM stages, as assessed on 
histopathological examination of resected speci-
mens, in relation to preoperative TNM status, 
are listed in Table 3. The complete pathological 
response was recorded in 5 patients (9.1%; 95% 
CI, 3%-20%). In an additional patient, only an 
isolated cluster of cancer cells was found in the 
extranodal perirectal fat tissue. All 5 patients 
with pathologically determined complete remis-
sion rate received more than 90% of the planned 
capecitabine dose and did not have any radio-
therapy interruption. Whereas the difference 
in pathologically determined complete remis-
sion rate between patients with (none out of 25 
patients) and without (5 out of 30 patients) ra-
diotherapy interruptions was marginally statisti-
cally significant (Fisher exact test, P =0 .056), the 
capecitabine dose that patients received (more 
vs less than 90% of the planned dose) had no in-
Table 2. Acute toxicity of preoperative chemoradiotherapy˝*
Toxicity grade (No., %)
Toxicity  1 2 3
Hematological:
 anemia  3 2
 leukocytopenia  5 2  1
Non-hematological:
 fatigue 14 1
 nausea 11
 vomiting  6
 hand and foot syndrome  4
 diarrhea 11 5  2
 infection  4 1  1
 impaired heart function  1
 radiodermatitis 15 1 19
 cystitis  5
 proctitis 12 1  1
*According to the National Cancer Institute Common Toxicity Criteria (version 2.0) (8)
Table 3. Distribution of postoperative pathological TNM (pTNM) stages compared to pretreatment clinical stages (cTNM) in 55 patients 
who underwent definitive surgery*
After surgery (pTNM)
Before surgery (cTNM) T0N0 T0N1 T1N0 T2N0 T2N1 T3N0 T3N1 T3N2 T4N0 T4N1 T4N2 T3N2M1
T1N1 1
T2N1 1 1
T3N0 1 1 7 7 3 1
T3N1 4 1 1 4 1 4 4 5 1
T3N2 2 1 1
T4N0 1
T4N1 1 1
Total (%) 5 (9.1) 1 (1.8) 3 (5.4) 13 (23.6) 1 (1.8) 12 (21.8) 9 (16.4) 6 (10.9) 1 (1.8) 1 (1.8) 1 (1.8) 2 (3.6)
*Abbreviations: T – tumor, N – node, M – metastasis (8) .
Croat Med J 2006;47:693-700
698
fluence on the rate of pathologically determined 
complete remission.
Preservation of anal sphincter
Before therapy, abdominoperineal resection was 
planned in 24 out of 55 patients who had defin-
itive surgery. After completion of chemoradio-
therapy, sphincter-conserving surgery was suc-
cessfully performed in 7 of these 24 patients. 
Among 31 patients in whom sphincter-conserv-
ing surgery was planned before having had any 
therapy, this was not possible in two patients, 
which resulted in an ultimate sphincter preser-
vation rate of 65.5% (36/55). In the subgroup of 
27 patients with tumors located within 5 cm of 
the anal opening, sphincter preservation was pos-
sible in 10 patients (37%).
Discussion
In the present prospective phase II study, 
capecitabine proved its safety and, from the view-
point of organ preservation had considerable 
downstaging potential, when combined with 
concomitant radiotherapy in the preoperative 
setting in patients with stage II-III rectal cancer.
Currently, chemoradiotherapy using 5-FU 
is considered the gold standard in the treatment 
of locally advanced rectal cancer in the neoadju-
vant setting (12). Given the short half-life of 5-
FU in plasma and its intracellular metabolites, it 
should be administered in the form of prolonged 
intravenous infusions during the course of frac-
tionated radiotherapy in order to act as a radio-
sensitizer (13-15). Moreover, infusional 5-FU is 
generally better tolerated than a bolus schedule 
(12,13). As oral capecitabine mimics continu-
ous 5-FU infusion, both from the standpoint of 
locoregional control and treatment-related toxic-
ity (16), we initiated this phase II study to evalu-
ate its toxicity and efficacy in combination with 
preoperative radiotherapy in patients with locally 
advanced rectal cancer.
According to the results of randomized tri-
als, short-course hypofractionated radiotherapy 
regimen (Swedish schedule, 5 fractions of 5 Gy 
delivered in 5 consecutive days) followed by im-
mediate surgery also reduces local recurrence rate 
and improves survival compared to surgery alone 
(17). However, this approach has not been ac-
cepted worldwide, mainly because a short inter-
val between radiotherapy and surgery allows nei-
ther tumor regression nor an increased ability of 
sphincter sparing surgery to be performed. In ad-
dition, the irradiation using 5 Gy fractions is as-
sociated with increased incidence of late effects, 
such as poor function of the anal sphincter and 
small bowel injury (18). Consequently, chemo-
therapy cannot be integrated into a large fraction 
regimen without excessive toxicity.
In the National Surgical Adjuvant Breast 
and Bowel Project Protocol R-03 (11) and in 
the German study by Sauer et al (1), which eval-
uated the effectiveness of the preoperative ap-
plication of continuous 5-FU infusion and ir-
radiation, pathologically determined complete 
remission rate was 8%. With oral capecitabine, 
pathologically determined complete remission 
rates, ranged from 4 to 31% mostly in prelimi-
nary studies (19-25), whereas in the recent study 
by Kim et al (26), which was the largest study so 
far, the pathologically determined complete re-
mission rate was 12%. In our study, the patholog-
ically determined complete remission rate was at 
somewhat lower rate of 9.1%. We presume that 
the main reason for this discrepancy was the un-
favorable distribution of T- and N-tumor stages 
in our patients; in 60% of them the preoperative 
stage of disease was T3-4 and/or N+. Further-
more, contrary to other authors, we did not add 
a booster dose after the lesser pelvis was irradiat-
ed to a tumor dose of 45 Gy (19-24). In spite of 
a relatively high radiation dose of 55.8 Gy, Dunst 
et al (20) reported a pathologically determined 
complete remission rate of only 4% in a popu-
lation of patients with a rather high proportion 
(50%) of T4 primaries. On the other hand, Du-
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pois et al (25) observed as much as a 24% patho-
logically determined complete remission rate af-
ter preoperative radiotherapy to a dose of 45 Gy; 
however, only 2% of the tumors from their study 
were stage T4.
The other reason for the lower pathological-
ly determined complete remission rate in our se-
ries could be the fact that the radiotherapy com-
ponent of the protocol was prolonged in as many 
as 45.5% of our patients, with treatment inter-
ruptions of 3 days or more introduced in 18.2% 
of them. In contrast, in the study by Kim et al 
(26), there were no radiotherapy interruptions 
of more than 2 days. Furthermore, we found that 
10.9% of patients received less than 90% of the 
planned dose of capecitabine which could also 
have reduced the likelihood of achieving the de-
sired pathologically determined complete remis-
sion rate even though this was not statistically sig-
nificant. Although the patients were thoroughly 
instructed before treatment and had diaries to fill 
in, which were monitored regularly by the radi-
ation oncologist, many of them did not follow 
the instructions. Compliance in oral therapy in 
comparison to intravenous treatment could be 
a drawback of this type of therapy.
In the subgroup of our patients with primary 
tumors located 5 cm or less from the anal open-
ing, the sphincter preservation rate was 37%, 
which is only half of 72% reported by Kim et al 
(26). In the latter study, all but one patient were 
operated on by a single surgeon, whereas in our 
study surgery was performed by 24 surgeons 
from 10 different hospitals. According to our 
previous experience, the level of expertise in pel-
vic surgery differs substantially among individual 
surgeons. Therefore, the probability of sphincter 
preservation in our series would most probably 
have been higher if all patients had been operat-
ed on by a limited number of highly skilled onco-
logical surgeons.
The second important limitation of our study 
is the diversity of diagnostic modalities used for 
staging purposes. We are aware that MRI of the 
lower abdomen and endoluminal ultrasound of 
the rectum are the two most adequate and used 
investigations to determine the pretreatment 
extent of the disease. However, as the magnetic 
resonance imaging (MRI) and endorectal ultra-
sound (EUS) capacities in Slovenia were limited 
at the time the study was conducted, we did not 
specify a radiologic procedure for disease evalua-
tion in our entry criteria. Consequently, we com-
pared the preoperative clinical stage of the disease 
as assessed by different radiological modalities 
with the postoperative pathological stage for the 
assessment of treatment efficacy.
In some studies, the financial aspect of che-
motherapy with oral capecitabine was also eval-
uated (27,28). Compared with intravenous ad-
ministration of 5-FU, the results speak in favor 
of oral capecitabine. However, the financial bene-
fit of any new regimen should be weighed against 
the long-term local control rate and patient sur-
vival rate and, finally, compared to a standard. As 
reliable data on these two endpoints for preoper-
ative chemoradiotherapy with oral capecitabine 
are not yet available, the overall cost-effectiveness 
analysis of this particular regimen must be post-
poned into the future.
According to the results of our study and 
data from the literature, we conclude that in pa-
tients with locoregionally advanced rectal can-
cer, preoperative chemoradiotherapy with oral 
capecitabine as a radiosensitizer is safe. This treat-
ment has considerable downstaging potential 
and can significantly increase the possibility of 
sphincter preservation in low-sited rectal primary 
tumors. Therefore, it seems that oral capecitabine 
represents a good alternative to protracted intra-
venous 5-FU in preoperative chemoradiothera-
py protocols from the standpoint of toxicity and 
downstaging potential. The effectiveness of this 
new regimen is to be defined through random-
ized controlled trial(s) comparing all aspects (ie, 
toxicity, efficacy, and costs) of oral capecitabine 
therapy and protracted intravenous 5-FU.
Croat Med J 2006;47:693-700
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